Author

Kanako Sakaeda

Observed names: K Sakaeda, K. Sakaeda

Institution: Sysmex (Japan)

Observed institution: Sysmex (Japan)

ORCID: 0000-0001-7412-9489

Observed ORCID: 0000-0001-7412-9489

OpenAlex ID: A5043653682

A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer

2021 · Yumiko Sakai, Koji Kurose, et al. · Clinica Chimica Acta · 13

Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers

2022 · Koji Kurose, Kanako Sakaeda, et al. · Advances in clinical chemistry · 5

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer

2024 · Kanako Sakaeda, Koji Kurose, et al. · Cancer Treatment and Research Communications · 4

A-213 Assessing the Function of High-Density Lipoprotein and the Risk of Cardiovascular Disease Using Fully Automated Immunoassay Analyzer, HISCLTM

2023 · J Kim, K Murakami, et al. · Clinical Chemistry

Abstract A61: Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC

2022 · Kanako Sakaeda, Koji Kurose, et al. · Cancer Immunology Research

EP08.01-064 Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC

2022 · M. Oka, K. Kurose, et al. · Journal of Thoracic Oncology

Abstract 3180: Development of a fully automated immunoassay system for detection of serum NY-ESO-1 and XAGE1 antibodies as biomarkers predicting the clinical efficacy of anti-PD-1 therapy

2020 · Yumiko Sakai, Hirotaka Abo, et al. · Cancer Research

Works count: 7

Citation count: 22

H-index: 3

I10-index: 1